Investigational drug · Phase 3
su vaccine
Also called: RZV
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Herpes Zoster, Respiratory Syncytial Virus (RSV).
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 6, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
43
Any phase or sponsor naming "su vaccine"
First trial start
2022
Aug 10, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "su vaccine", any sponsor or status.
- Phase 326
Conditions studied
As listed on its trial records.
- Herpes Zoster
- Respiratory Syncytial Virus (RSV)
Approved drugs for the same conditions: RSV · Herpes and shingles · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "su vaccine" as an intervention, largest first.
- Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)Pivotal-lookingCompleted
Health Institutes of TurkeyGovernment (non-federal)
NCT04582344 · 10,214 participants · Start Sep 14, 2020 · Primary completion Jun 30, 2022
Drug: CoronaVac; Placebo · For: COVID-19
Sites: Ankara, Turkey (Türkiye); Adana, Turkey (Türkiye); Antalya, Turkey (Türkiye) · 25 sites in all
- Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02690207 · 8,687 participants · Start Mar 16, 2016 · Primary completion Mar 15, 2019
Drug: Herpes Zoster Vaccine GSK1437173A · For: Herpes Zoster
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 195 sites in all
GlaxoSmithKlineGSK (GSK)
NCT02723773 · 7,539 participants · Start Apr 16, 2016 · Primary completion Jun 28, 2023
Drug: Herpes Zoster Vaccine GSK1437173A · For: Herpes Zoster; Herpes Zoster Vaccine
Sites: Phoenix, Arizona; Spring Valley, California; Hallandale, Florida · 161 sites in all
Fundação de Medicina Tropical Dr. Heitor Vieira DouradoAcademic, hospital or other
NCT04789356 · 6,233 participants · Start Mar 18, 2021 · Primary completion Jul 5, 2021
Drug: Adsorbed SARS-CoV-2 (inactivated) vaccine · For: Covid19
Sites: Manaus, Brazil
- A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older AdultsPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT05371080 · 3,038 participants (planned) · Start Aug 10, 2022 · Primary completion Aug 23, 2027
Drug: HZ/su vaccine · For: Herpes Zoster
Sites: Phoenix, Arizona; Elkridge, Maryland; Charlotte, North Carolina · 107 sites in all
- A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster VaccinePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05047770 · 2,013 participants · Start Oct 7, 2021 · Primary completion Aug 29, 2022
Drug: HZ/su; mRNA-1273 · For: Herpes Zoster
Sites: Tempe, Arizona; Oxnard, California; San Diego, California · 46 sites in all
- Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes ZosterPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04091451 · 1,430 participants · Start Sep 17, 2019 · Primary completion Feb 15, 2024
Drug: Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A); Placebo · For: Herpes Zoster
Sites: Barnaul, Russia; Gatchina, Russia; Moscow, Russia
- Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), InactivatedPivotal-lookingStatus unknown
Sinovac Biotech (Colombia) S.A.S.Industry
NCT05433272 · 1,400 participants (planned) · Start Aug 10, 2023 · Primary completion Sep 10, 2023
Drug: Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain; COVID-19 Vaccine (Vero Cell), Inactivated · For: COVID-19
Sites: Barranquilla, Colombia
- Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years OldPivotal-lookingActive, not recruiting
Sinovac Biotech Co., LtdIndustry
NCT06058416 · 1,092 participants · Start Oct 24, 2023 · Primary completion Mar 17, 2028
Drug: Healive (hepatitis A vacine(human diploid cell), inactivated) · For: Hepatitis A
Sites: Shenyang, China
GlaxoSmithKlineGSK (GSK)
NCT02052596 · 935 participants · Start Feb 7, 2014 · Primary completion Jun 16, 2015
Drug: Herpes Zoster vaccine GSK 1437173A; Boostrix · For: Herpes Zoster
Sites: Tucson, Arizona; San Diego, California; Stockbridge, Georgia · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Transient clinical improvement and immune modulation following recombinant Zoster vaccination in a patient with ME/CFS.
Bigleri A, Alimo ET, Abouda A, et al. · Brain Behav Immun Health 2026
- Brief report: Effectiveness and safety of recombinant zoster vaccine in inflammatory bowel disease patients aged 18 years and older: A matched cohort and self-controlled case series study.
Humayun M, Sy LS, Rayens E, et al. · Hum Vaccin Immunother 2026
- Burden of herpes zoster and recombinant zoster vaccine willingness in systemic lupus erythematosus: A single-center cohort study.
Fujisawa Y, Watanabe R, Ishihara R, et al. · Lupus 2026
- Priority setting for older adult vaccines in Indonesia: a multi-criteria decision analysis using SMART vaccines.
Alfaqeeh M, Zakiyah N, Postma MJ, et al. · Expert Rev Vaccines 2026
- Feasibility and safety of recombinant zoster vaccination in patients undergoing active cancer treatments: A real-world single-center experience.
Ciappina G, Di Mauro G, Toscano E, et al. · Hum Vaccin Immunother 2026
- Fc-mediated immune effector functions elicited by recombinant and live-attenuated herpes zoster vaccines.
Huang Z, Jin P, Pan H, et al. · Expert Rev Vaccines 2026
Also in development for Herpes Zoster
- CHO Cellrecombinant zoster vaccine, Recombinant Respiratory Syncytial Virus VaccinePhase 39 trials
MAXVAX Biotechnology Limited Liability Company · Herpes Zoster, Respiratory Syncytial Virus (RSV), Herpes Zoster (HZ)
- Active Comparator vaccinePhase 36 trials
Sinovac Biotech Co., Ltd · Epidemic Meningitis, Meningococcal Vaccines, Herpes Zoster
- SCTV04CRecombinant Herpes Zoster Vaccine -DosePhase 21 trial
Sinocelltech Ltd. · Herpes Zoster
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.